Wang Manni, Ma Xuelei, Zhu Chenjing, Guo Linghong, Li Qingfang, Liu Ming, Zhang Jing
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, PR China.
West China Hospital, Sichuan University, Chengdu, PR China.
Oncotarget. 2016 Dec 6;7(49):81292-81304. doi: 10.18632/oncotarget.13223.
Reports have demonstrated the prognostic function of long non-coding RNAS (lncRNAS) in patients with cancer. However, their prognostic functions in non small cell lung cancer (NSCLC) remain controversial. We therefore performed a meta-analysis on six lncRNAs (PVT1, AFAP1-AS1, LINC01133, ANRIL, MEG3 and UCA1) to clarify their prognostic roles in NSCLC.
Thirty-six studies involving 6267 patients with NSCLC and 34 lncRNAs were included. Of the listed lncRNAs, 20 were shown to negatively affect patients' overall survival while the high expression of 13 lncRNAs indicated better survival outcomes.
The log-rank p value and Kaplan-Meier survival curves of survival outcomes were extracted for hazard ratio (HR) calculation. Survival outcomes were measured by overall survival (OS) and event free survival (EFS) which were then analyzed by calculating pooled hazard ratios. The heterogeneity was detected by Q statistic and I-squared statistic.
The abnormal expression of lncRNAs may significantly affect NSCLC patients' survival and may serve as a novel predictive factor for prognosis of NSCLC patients.
有报告显示长链非编码RNA(lncRNA)在癌症患者中具有预后功能。然而,它们在非小细胞肺癌(NSCLC)中的预后功能仍存在争议。因此,我们对六种lncRNA(PVT1、AFAP1-AS1、LINC01133、ANRIL、MEG3和UCA1)进行了荟萃分析,以阐明它们在NSCLC中的预后作用。
纳入了36项研究,涉及6267例NSCLC患者和34种lncRNA。在所列的lncRNA中,20种被证明对患者的总生存期有负面影响,而13种lncRNA的高表达表明生存结果更好。
提取生存结果的对数秩p值和Kaplan-Meier生存曲线以计算风险比(HR)。生存结果通过总生存期(OS)和无事件生存期(EFS)来衡量,然后通过计算合并风险比进行分析。通过Q统计量和I²统计量检测异质性。
lncRNA的异常表达可能显著影响NSCLC患者的生存,并可能作为NSCLC患者预后的一种新的预测因素。